FBXW7 and SMAD4 (SMAD, Mothers Against DPP Homolog 4) mutations are prevalent in CRC patients resistant to anti-epidermal growth factor receptor (EGFR) immunotherapy treatment (monoclonal antibodies, Cetuximab or Panitumumab) [116]. Here, FBXW7 is linked to colorectal carcinoma.